This is a cpff to to refurbish APA buildings 1034
Active Awarded Last action
- Contract number
- 75N91022F00031
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,274,892
Award facts
- Contract value 100% obligated
- $6,274,892.00 Current and potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$207,640 | |
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $797,385 | |
| Other Administrative Action | $0 | |
| Original award | $5,685,147 |
About this award
The National Cancer Institute awarded a $6.27 million cost-plus-fixed-fee delivery order to Leidos Biomedical Research Inc. for the refurbishment of Building 1034 at the Frederick, Maryland campus. This delivery order, issued on September 23, 2022, is structured as part of a larger contract vehicle and carries an ultimate completion date of February 5, 2027. The award includes an implementation component aligned with the President's Department of Government Efficiency cost efficiency initiative as of March 19, 2025. No small business set-aside was utilized for this procurement, reflecting Leidos Biomedical Research Inc.'s competitive capabilities as a Federally Funded Research and Development Center contractor.
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., specializes in comprehensive biomedical research and facilities support services for the National Cancer Institute and National Institutes of Health. The company's extensive experience delivering cost-plus-fixed-fee contracts for research infrastructure and operational support positions it well to execute this facilities refurbishment project. The Frederick location serves as a critical hub for federal biomedical research operations, and this refurbishment effort supports the continuation and enhancement of research capabilities at the National Cancer Institute's facility.
Quick answers
Who was awarded contract 75N91022F00031?
75N91022F00031 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 23, 2022.
How much is contract 75N91022F00031 worth?
The government has obligated $6,274,892 on 75N91022F00031.
Is contract 75N91022F00031 an order under another contract?
Yes. 75N91022F00031 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00031 competed?
The extent of competition for 75N91022F00031 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award